Ashita Tolwani
Nephrology · Birmingham, ALNPI 1073533824
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (51.9%), speaking fees and education — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Baxter Healthcare at 54.0% of the total. Among nephrology clinicians in AL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 50 payments — averaging $1117.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Baxter Healthcare$30K
- Vantive US Healthcare LLC$12K
- Outset Medical Inc$5K
- Biomerieux Inc$5K
- Fresenius USA Marketing, Inc.$4K
- Mallinckrodt Hospital Products Inc.$265
- plus $115 from 1 others
Across 21 payments — averaging $1777.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astute Medical, Inc.$37K
What the payments were for
- Consulting fees$28,96852%
- Speaking & faculty fees$13,40524%
- Travel & lodging$2,3674%
- Food & beverage$1,5503%
- Education$9,57417%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Baxter Healthcare | 33 | $30,171 |
| Vantive US Healthcare LLC | 9 | $11,538 |
| Outset Medical Inc | 3 | $5,075 |
| Biomerieux Inc | 1 | $4,800 |
| Fresenius USA Marketing, Inc. | 1 | $3,900 |
| Mallinckrodt Hospital Products Inc. | 2 | $265 |
| Nxstage Medical, Inc. | 1 | $115 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Renal - Acute$28,294
- Renal - Non Product Related$6,935
- Renal - Prismocitrate$3,400
- Renal - PD$1,400
- Renal - CRRT$850
- Non-Franchise (NOF) - NonProduct$286
- TERLIVAZ$265
- NOVALUNG SYSTEM$115
- NXSTAGE SYSTEM ONE$115
How this compares
$55,863 in reported general payments places this provider in the 90th percentile of 164 nephrology providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 14 | $10,039 |
| Losartan Potassium | 41 | $327 |
| Carvedilol | 36 | $226 |
| Furosemide | 15 | $186 |
| Amlodipine Besylate | 24 | $171 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Birmingham
- Dana RizkBirmingham$196K
- Eric WallaceBirmingham$172K
- David WarnockBirmingham$128K
- Michal MrugBirmingham$73K
- Vineeta KumarBirmingham$59K
- Song Ching OngBirmingham$36K
- Orlando GutierrezBirmingham$26K
- Ammar AlmehmiBirmingham$26K
- Jared CookBirmingham$25K
- Timmy LeeBirmingham$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.